We serve Chemical Name:1,2-Di(1-naphthyl)ethane CAS:15374-45-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,2-Di(1-naphthyl)ethane
CAS.NO:15374-45-5
Synonyms:1,2-Di(1-naphthyl)ethane;MFCD00037736;Ethane, 1,2-di-1-naphthyl-;1,1′-(1,2-Ethanediyl)dinaphthalene;1,2-BIS(1-NAPHTHYL)ETHANE;Naphthalene, 1,1′-(1,2-ethanediyl)bis-;1,1′-Ethane-1,2-diyldinaphthalene;1-(2-naphthalen-1-ylethyl)naphthalene
Molecular Formula:C22H18
Molecular Weight:282.378
HS Code:2902909090
Physical and Chemical Properties:
Melting point:161-162°C
Boiling point:447.5±15.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.690
PSA:
Exact Mass:282.140839
LogP:7.16
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1,2-Di(1-naphthyl)ethane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(2-naphthalen-1-ylethyl)naphthalene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,1′-Ethane-1,2-diyldinaphthalene Use and application,1,2-BIS(1-NAPHTHYL)ETHANE technical grade,usp/ep/jp grade.
Related News: The CHMP concluded that the benefits of Zynteglo continue to outweigh its risks. As for all medicines, the EMA will monitor any new data on its safety and update advice for patients and healthcare professionals when necessary. S-(2-trimethylsilylphenyl)-N,N-dimethylaminothiocarbamate manufacturers The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. Methyl-phosphonothioic acid S-ethyl ester O-(2-ethylsulfanyl-ethyl) ester suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 5,6,7,8,10,10-hexachloro-4-methyl-3a,4,4a,5,8,8a,9,9a-octahydro-5,8-methanonaphtho[2,3-c]furan-1,3-dione vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 5,6,7,8,10,10-hexachloro-4-methyl-3a,4,4a,5,8,8a,9,9a-octahydro-5,8-methanonaphtho[2,3-c]furan-1,3-dione vendor & factory.
